{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:01:05Z","timestamp":1774969265153,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Bristol-Myers Squibb Co Summit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ijrobp.2024.01.002","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T20:24:23Z","timestamp":1704745463000},"page":"1519-1530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials"],"prefix":"10.1016","volume":"118","author":[{"given":"Connor","family":"Lynch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C.","family":"Korpics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan R.","family":"Katipally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M.","family":"Bestvina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Pitroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Chmura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Juloori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.01.002_bib0001","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13014-018-1185-9","article-title":"Phase II trial on SBRT for unresectable liver metastases: Long-term outcome and prognostic factors of survival after 5\u2009years of follow-up","volume":"13","author":"Scorsetti","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","article-title":"Stereotactic body radiotherapy (SBRT) for liver metastasis \u2013 clinical outcomes from the international multi-institutional RSSearch\u00ae Patient Registry","volume":"13","author":"Mahadevan","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0003","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.ijrobp.2020.11.045","article-title":"The Dutch\u2013Belgian registry of stereotactic body radiation therapy for liver metastases: Clinical outcomes of 515 patients and 668 metastases","volume":"109","author":"Romero","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0004","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0005","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0007","article-title":"The impact of liver metastasis on anti-PD-1 monoclonal antibody monotherapy in advanced melanoma: Analysis of five clinical studies","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0008","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0009","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007218","article-title":"Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer","volume":"11","author":"Deng","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0011","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0012","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy versus pembrolizumab alone on tumor response in patients with advanced non\u2013small cell lung cancer","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0013","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijrobp.2020.08.018","article-title":"A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma","volume":"109","author":"Mahmood","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0014","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: An open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.629722","article-title":"Tumor burden and immunotherapy: Impact on immune infiltration and therapeutic outcomes","volume":"11","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0016","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","article-title":"Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: The CHEERS phase 2 randomized clinical trial","volume":"9","author":"Spaas","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0018","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/s43018-022-00467-x","article-title":"Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade","volume":"3","author":"Spurr","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0019","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2023.04.019","article-title":"YTHDF2 inhibition potentiates radiotherapy antitumor efficacy","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0020","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0021","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1158\/1078-0432.CCR-21-0810","article-title":"Phase I study of stereotactic body radiotherapy plus nivolumab and urelumab or cabiralizumab in advanced solid tumors","volume":"27","author":"Foster","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0022","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0023","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.prro.2016.05.004","article-title":"Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases","volume":"6","author":"Al-Hallaq","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0024","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaoncol.2021.0687","article-title":"Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: Findings from the NRG-BR001 phase 1 trial","volume":"7","author":"Chmura","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0026","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7150\/jca.1.80","article-title":"Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST","volume":"1","author":"Costelloe","year":"2010","journal-title":"J Cancer"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0027","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0028","unstructured":"R Core Team. R: A language and environment for statistical computing. Available at: https:\/\/ringo.ams.stonybrook.edu\/images\/2\/2b\/Refman.pdf. Accessed August 1, 2023."},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v098.i11","article-title":"cutpointr: Improved estimation and validation of optimal cutpoints in R","volume":"98","author":"Thiele","year":"2021","journal-title":"J Stat Soft"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12880-015-0068-x","article-title":"Metrics for evaluating 3D medical image segmentation: Analysis, selection, and tool","volume":"15","author":"Taha","year":"2015","journal-title":"BMC Med Imaging"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0031","unstructured":"Therneau TM, Lumley T, Elizabeth A, Cynthia C. survival: Survival analysis. Available at: https:\/\/cran.r-project.org\/web\/packages\/survival\/index.html. Accessed August 3, 2023"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0032","unstructured":"Wickham H, Chang W, Henry L, et al. ggplot2: Create elegant data visualisations using the grammar of graphics. Available at: https:\/\/cran.r-project.org\/web\/packages\/ggplot2\/index.html. Accessed August 3, 2023"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0033","unstructured":"Kassambara A, Kosinski M, Biecek P, Fabian S. survminer: Drawing survival curves using \u201cggplot2\u201d. Available at: https:\/\/cran.r-project.org\/web\/packages\/survminer\/index.html. Accessed August 3, 2023"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0034","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0035","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.ijrobp.2024.01.002_bib0036","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/jrr\/rrx104","article-title":"Strategies for prediction and mitigation of radiation-induced liver toxicity","volume":"59","author":"Toesca","year":"2018","journal-title":"J Radiat Res"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0037","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ijrobp.2005.01.002","article-title":"A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases","volume":"62","author":"Schefter","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0038","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1245\/s10434-010-1405-5","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases","volume":"18","author":"Rule","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0039","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00432-014-1833-x","article-title":"Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0040","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/j.prro.2017.03.004","article-title":"Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy","volume":"7","author":"Barry","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0041","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2020.01.009","article-title":"Validation of RTOG 0813 proximal bronchial tree constraints for pulmonary toxicity with stereotactic body radiation therapy for central non-small cell lung cancer","volume":"107","author":"Manyam","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0042","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0043","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2017.01.221","article-title":"Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma","volume":"97","author":"Velec","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0044","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0045","first-page":"45","article-title":"High versus low dose stereotactic body radiation therapy for hepatic metastases","volume":"20","author":"Kok","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0046","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0047","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/acm2.13204","article-title":"Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS)","volume":"22","author":"Rokni","year":"2021","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0048","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ijrobp.2022.06.068","article-title":"Predictors of pneumonitis in combined thoracic stereotactic body radiation therapy and immunotherapy","volume":"114","author":"Korpics","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.01.002_bib0049","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","article-title":"The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis","volume":"21","author":"Kotecha","year":"2019","journal-title":"Neuro Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:12:11Z","timestamp":1759745531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0360301624000075"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.002","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}